



Quick-Med Technologies to Receive US Patent on Novel Antimicrobial Technology Based on Hydrogen Peroxide

Durable, Eco-Friendly Stay Fresh Antimicrobial Provides Extended Protection for Textiles

GAINESVILLE, FL -- (MARKETWIRE) -- 09/12/12 -- Quick-Med Technologies, Inc. (OTCQB: QMDT), a life sciences company focused on developing antimicrobial technologies for healthcare and consumer markets, announced today that the US Patent and Trademark Office has issued a notice of allowance for a patent protecting *Stay Fresh*[®], Quick-Med's revolutionary new antimicrobial technology.

"It is very exciting to receive this allowance, which confirms the unique nature of our *Stay Fresh Antimicrobial* technology," commented Bernd Liesenfeld, president of Quick-Med Technologies. "This allows us to offer our partners a very well protected license position for our unique hydrogen peroxide based antimicrobial, which is already EPA-registered."

Stay Fresh Antimicrobial technology is eco-friendly, safe, non-toxic, and cost effective. Textiles treated with *Stay Fresh* have been proven to retain potent antimicrobial activity for as many as 100 wash cycles, with reduction of bacterial levels by up to 99.9999%. The active antimicrobial agent utilized in *Stay Fresh* is hydrogen peroxide, which is non-toxic, and degrades to eco-friendly water and oxygen.

As consumers are becoming more aware of the environmental and toxicological impacts of the products that enter their households, companies are under increasing pressure to offer ecologically friendly solutions. One established consumer antimicrobial that has recently received increasing public attention and concern is triclosan [5-chloro-2-(2,4-dichlorophenoxy)phenol], with concerns including possible degradation to dioxin products, and a recent study reported in the Proceedings of the National Academy of Sciences demonstrating that exposure to triclosan can lead to muscle weakening in lab animals (<http://www.pnas.org/content/109/35/14158.abstract>). Quick-Med Technologies provides

effective, durable and easy to implement antimicrobial technologies that offer safe alternatives to aging competing technologies, and allow manufacturers to develop value-enhanced products for their customers.

Originally developed to meet the demanding requirements of a military uniform application, Quick-Med began its *Stay Fresh* commercialization efforts with apparel and other consumer textile applications. The Company has since expanded its focus to include medical devices and has filed a 510(k) Premarket Notification with the U.S. Food and Drug Administration for a device that incorporates *Stay Fresh* Antimicrobial technology.

About Stay Fresh Antimicrobial

Stay Fresh Antimicrobial is Quick-Med's newest technology platform, offering a breakthrough in antimicrobial protection. Today's leading freshness-enhancing textile technologies are unable to control certain bacteria and unable to maintain efficacy throughout the life of the product. *Stay Fresh* is designed to overcome these limitations by providing cost-effective, durable, and sustained antimicrobial protection. The safe, eco-friendly active ingredient in *Stay Fresh* is bonded to fibers or fabrics, and retains its efficacy for as many as 100 laundering cycles, in hot or cold water.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets.

Stay Fresh[®], Quick-Med's latest core-technology, joins NIMBUS[®], used in wound dressings, and NimbuDerm[™], a technology being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.

© 2012 Quick-Med Technologies, Inc. All rights reserved. NIMBUS[®] and *Stay Fresh*[®] are registered trademarks and NimbuDerm[™] is a trademark of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

Note: Antimicrobial information is presented solely to assist in technology evaluation and is not intended to be a public health claim.

CONTACT:

Quick-Med Technologies

Bernd Liesenfeld, Ph.D.

President

(888) 835.2211 Ext 103

[Email Contact](#)